drugset / Trial / NCT05872347

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

NCT05872347

Phase 2 Recruiting 52 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.

Timeline

Start
2023-09-19
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SPH4336 Unknown Oral
Background Exemestane Small molecule Oral
Background Fulvestrant Small molecule Intravenous
Background Letrozole Other / unclassified Oral